Skip to main content

Stryker Corporation guidance

  • SYK · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$317.49+2.18%Close 17 Nov 2026 · Market value $121.4B

In its results release of 29 Oct 2026 (Q3 FY2026), Stryker Corporation gave 2 forecasts in figures, among them EPS (adjusted) of $14.80 to $14.90 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
Organic revenue growthFY2026+6.5% to +7%We are updating our full year 2026 guidance and now expect organic net sales growth in the range of 6.5% to 7.0% and adjusted net earnings per diluted share to be in the range of $14.80 to $14.90
EPS · AdjustedFY2026$14.80 to $14.90We are updating our full year 2026 guidance and now expect organic net sales growth in the range of 6.5% to 7.0% and adjusted net earnings per diluted share to be in the range of $14.80 to $14.90

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Organic revenue growthFY2026+6.5% to +7%Lowered once—To come
EPS · AdjustedFY2026$14.80 to $14.90Raised once, lowered once—To come

SYK in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.